Drug Profile
Trastuzumab biosimilar - Mycenax Biotech
Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Mycenax Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Breast-cancer in Taiwan (Parenteral)
- 09 Aug 2017 Trastuzumab biosimilar - Mycenax Biotech is available for licensing as of 09 Aug 2017. http://www.mycenax.com.tw/en/goods.php?act=view&no=6
- 09 Aug 2017 Early research in Breast cancer in Taiwan (Parenteral) before August 2017 (Mycenax Biotech pipeline, August 2017)